An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Sánchez Gomar, Ismael ^a   Díaz Sánchez, María ^a   Uclés Sánchez, Antonio J ^a   Casado Chocán, José L ^a   Ramírez Lorca, Reposo ^a   Serna, Ana ^a   Villadiego, Javier ^a   Toledo Aral, Juan J ^a,b   Echevarría, Miriam ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

AQP4 EGFP; HEK cells; Immunohistochemistry; Natalizumab; NMO IgG

Indexed keywords

AQUAPORIN 4 ANTIBODY; ENHANCED GREEN FLUORESCENT PROTEIN; NATALIZUMAB; AQP4 PROTEIN, HUMAN; AQUAPORIN 4; AUTOANTIBODY; AUTOANTIGEN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; EMBRYO; FEMALE; FREEZE THAWING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IDIOPATHIC MYELITIS; IMMUNOFLUORESCENCE TEST; IMMUNOGOLD LABELING; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; OPTIC NEURITIS; AGED; IDIOPATHIC DISEASE; IMMUNOASSAY; ADOLESCENT; BLOOD; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; MIDDLE AGED; NEUROMYELITIS OPTICA; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUAPORIN 4; AUTOANTIBODIES; AUTOANTIGENS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; YOUNG ADULT;

EID: 84904098587     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-14-139     Document Type: Article

References (30)

1. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6:805-815.
2. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
3. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
4. Jarius S, Franciotta D, Bergamaschi R, Wright H, Littleton E, Palace J, Hohlfeld R, Vincent A. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007, 68:1076-1077.
5. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006, 63:964-968.
6. Amiry-Moghaddam M, Hoddevik EH, Ottersen OP. Aquaporins: multifarious roles in brain. Neuroscience 2010, 168:859-861.
7. Zelenina M. Regulation of brain aquaporins. Neurochem Int 2010, 57:468-488.
8. Venero JL, Vizuete ML, Ilundain AA, Machado A, Echevarria M, Cano J. Detailed localization of aquaporin-4 messenger RNA in the CNS: preferential expression in periventricular organs. Neuroscience 1999, 94:239-250.
9. Nakamura M, Endo M, Murakami K, Konno H, Fujihara K, Itoyama Y. An autopsied case of neuromyelitis optica with a large cavitary cerebral lesion. Mult Scler 2005, 11:735-738.
10. Cayrol R, Saikali P, Vincent T. Effector functions of antiaquaporin-4 autoantibodies in neuromyelitis optica. Ann N Y Acad Sci 2009, 1173:478-486.
11. Fujihara K. Neuromyelitis optica and astrocytic damage in its pathogenesis. J Neurol Sci 2011, 306:183-187.
12. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, Lassmann H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125:1450-1461.
13. Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, Mandler RN, Weinshenker BG, Pittock SJ, Wingerchuk DM, Lucchinetti CF. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007, 130:1194-1205.
14. Hinson SR, McKeon A, Lennon VA. Neurological autoimmunity targeting aquaporin-4. Neuroscience 2010, 168:1009-1018.
15. Santiesteban NJ, Marrero M, González TM, Armenteros VK. Neuromielitis óptica. Neurocirujía 2009, 33:72-77.
16. Saiz A, Zuliani L, Blanco Y, Tavolato B, Giometto B, Graus F. Revised diagnostic criteria for neuromyelitis optica (NMO). J Neurol 2007, 254:1233-1237.
17. Fazio R, Malosio ML, Lampasona V, De Feo D, Privitera D, Marnetto F, Centonze D, Ghezzi A, Comi G, Furlan R, Martino G. Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients. Mult Scler 2009, 15:1153-1163.
18. McKeon A, Fryer JP, Apiwattanakul M. Diagnosis of neuromyelitis spectrum disorders: Comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol 2009, 66:1134-1138.
19. Waters P, Vincent A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J 2008, 15:99-105.
20. Jarius S, Paul F, Franciotta D, Waters P, Zipp F, Hohlfeld R, Vincent A, Wildemann B. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 2008, 4:202-214.
21. Paul F, Jarius S, Aktas O, Bluthner M, Bauer O, Appelhans H, Franciotta D, Bergamaschi R, Littleton E, Palace J, Seelig HP, Hohlfeld R, Vincent A, Zipp F. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 2007, 4:e133.
22. Waters P, Jarius S, Littleton E. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008, 65:913-919.
23. Hayakawa S, Mori M, Okuta A, Kamegawa A, Fujiyoshi Y, Yoshiyama Y, Mitsuoka K, Ishibashi K, Sasaki S, Hattori T, Kuwabara S. Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol 2008, 196:181-187.
24. Jarius S, Franciotta D, Paul F, Bergamaschi R, Rommer PS, Ruprecht K, Ringelstein M, Aktas O, Kristoferitsch W, Wildemann B. Testing for antibodies to human aquaporin-4 by ELISA: Sensitivity, specificity, and direct comparison with immunohistochemistry. J Neurol Sci 2012, 320:32-37.
25. Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, Watanabe S, Ishii N, Itoyama Y. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med 2006, 210:307-313.
26. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 2011, 69:292-302.
27. Abreu-Rodríguez I, Sánchez Silva R, Martins AP, Soveral G, Toledo-Aral JJ, López-Barneo J, Echevarría M. Functional and transcriptional induction of aquaporin-1 gene by hypoxia; analysis of promoter and role of Hif-1alpha. PLoS One 2011, 6:e28385.
28. Crane JM, Lam C, Rossi A, Gupta T, Bennett JL, Verkman AS. Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1/M23 isoforms and orthogonal arrays. J Biol Chem 2011, 286:16516-16524.
29. Nicchia GP, Mastrototaro M, Rossi A, Pisani F, Tortorella C, Ruggieri M, Lia A, Trojano M, Frigeri A, Svelto M. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia 2009, 57:1363-1373.
30. Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, Barkhof F, Polman CH, Wolbink G, Killestein J. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler 2013, 19:593-600.